Aprea Therapeutics
APRE
66 hedge funds and large institutions have $50.3M invested in Aprea Therapeutics in 2020 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 25 increasing their positions, 16 reducing their positions, and 13 closing their positions.
56% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 16
15% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 13
3% more funds holding
Funds holding: 64 → 66 (+2)
1.54% less ownership
Funds ownership: 3.97% → 2.43% (-1.5%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
88% less capital invested
Capital invested by funds: $404M → $50.3M (-$354M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$9.63M |
| 2 |
BlackRock
New York
|
+$8.09M |
| 3 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$5.39M |
| 4 |
CCM
CAAS Capital Management
New York
|
+$4.38M |
| 5 |
Two Sigma Investments
New York
|
+$3.78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$45.1M |
| 2 |
CCM
Consonance Capital Management
New York
|
-$35.1M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$23.8M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$20.5M |
| 5 |
5VM
5AM Venture Management
San Francisco,
California
|
-$19.9M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
TD Asset Management
Toronto,
Ontario, Canada
| – | -$411K | -854 | Closed |
|
77
State of Wisconsin Investment Board
Madison,
Wisconsin
| – | -$241K | -500 | Closed |
|
78
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$48K | -100 | Closed |
|
79
Daiwa Securities Group
Tokyo,
Japan
| – | +$951 | +2 | New |
|
APRE Hedge Fund Activity: Q4 2020 in Review
66 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Aprea Therapeutics (APRE) for Q4 2020, worth a combined $50.3M — down 88% from $404M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new APRE positions and 13 closed out — a net gain of 2 holders — while 25 added to existing stakes and 16 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $9.63M. The largest seller was Fidelity Investments, cutting an estimated $45.1M.
- 66 institutional investors held Aprea Therapeutics (APRE) as of Q4 2020, up from 64 in Q3 2020.
- Funds reported $50.3M of Aprea Therapeutics stock for Q4 2020, down 88% quarter-over-quarter.
- 15 funds opened new Aprea Therapeutics positions in Q4 2020 and 13 closed out, a net change of +2 holders.
- The largest Aprea Therapeutics buyer in Q4 2020 was Morgan Stanley, an estimated $9.63M added.
- The largest Aprea Therapeutics seller in Q4 2020 was Fidelity Investments, an estimated $45.1M sold.
Based on aggregated 13F filings for Q4 2020.